About the Company
kezar life sciences, inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the united states. the company's lead product candidate is kzr-616, a selective immunoproteasome inhibitor that is in phase 2 clinical trials across five autoimmune indications, including lupus nephritis, autoimmune hemolytic anemia, immune thrombocytopenia, dermatomyositis, and polymyositis; and phase 1b/2 clinical trials in systemic lupus erythematosus and lupus nephritis. its preclinical products include kzr-616, a selective immunoproteasome inhibitor for the treatment of various autoimmune disease indications; and kzr-tbd for the treatment of oncology and autoimmunity. the company was founded in 2015 and is headquartered in south san francisco, california.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
81
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $KZR News
KZR Stock Earnings: Kezar Life Sciences Misses EPS for Q4 2023
KZR stock results show that Kezar Life Sciences missed analyst estimates for earnings per share the fourth quarter of ...
Kezar Life Sciences Inc KZR
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
2023 Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today reported financial results ...
Buy Rating Affirmed for Kezar Life Sciences Amidst Progress in Lupus Nephritis Treatment and Expansion into Chinese Market
Kezar Life Sciences (KZR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on ...
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation ...
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif., February 28, 2024--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune ...
Kezar Life Sciences Inc.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Kezar Life Sciences Inc (2KZ.BE)
SOUTH SAN FRANCISCO, Calif., February 28, 2024--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing breakthrough treatments for immune-mediated and oncologic ...
Kezar Life Sciences Inc (KZR)
Gainers Kezar Life Sciences, Inc. (NASDAQ: KZR) rose 78% to $10.29 in pre-market trading after the company reported positive topline results from the MISSION Phase 2 clinical... After-Hours Stock ...
Loading the latest forecasts...